aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
aTyr Pharma announced publication of Phase 3 EFZO-FIT results for efzofitimod in pulmonary sarcoidosis in The Lancet Respiratory Medicine. The 268-patient trial missed its primary endpoint of statistically significant steroid reduction versus placebo, but efzofitimod improved multiple patient-reported outcomes, maintained lung function, and was well-tolerated. Lead author Daniel Culver called it the largest interventional trial ever conducted in pulmonary sarcoidosis and said results could shift how patients are managed and new therapies evaluated.
Key figures
- Drug Name
- efzofitimod
- Phase Of Trial
- Phase 3
- Primary endpoint
- change from baseline in mean daily oral corticosteroid dose at week 48 (not met)
- Patients enrolled
- 268
- Trial duration weeks
- 48
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.